 |
|
Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience
Min-Young Lee, Seug Yun Yoon, Kyoung Ha Kim, Namsu Lee, Ha Youn Kim, Jung Hwa Hwang, Jong-Ho Won
Korean J Intern Med. 2021;36(3):689-698. Published online 2021 Jan 8 DOI: https://doi.org/10.3904/kjim.2020.295
|
|
Citations to this article as recorded by
 Risk assessment based on dose-responsive and time-responsive genes to build PLS-DA models for exogenously induced lung injury
Lijuan Huang, Zinan Zhang, Huanchun Xing, Yuan Luo, Jun Yang, Xin Sui, Yongan Wang
Ecotoxicology and Environmental Safety.2023; 256: 114891. CrossRef Bevacizumab/cetuximab
Reactions Weekly.2021; 1868(1): 113. CrossRef Lung Injury Induced by Antitumor Drugs: Diagnosis, Features of the Clinical Course, Risk Factors, Differential Diagnosis, Treatment, and Prevention. Part 1
N. V. Orlovа, O. D. Ostroumovа, E. V. Shikh, S. V. Smerdin, E. V. Rebrovа, V. А. Dyo
Tuberculosis and Lung Diseases.2021; 99(7): 55. CrossRef Lung Injury Induced by Antitumor Drugs: Prevalence, Certain Drugs and Their Mechanisms of Action. Part 2
N. V. Orlova, O. D. Ostroumova, E. V. Shikh, S. V. Smerdin, E. V. Rebrova, V. А. Dyo
Tuberculosis and Lung Diseases.2021; 99(8): 54. CrossRef
|